Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition : A Randomized Controlled Trial on Vortioxetine
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature..
INTRODUCTION: To date, there are no therapeutics that have gained regulatory approval by the United States Food and Drug Administration (FDA) for the treatment of post-COVID-19 condition (PCC), a debilitating condition characterized by cognitive impairment and mood symptoms. Additionally, persistent inflammation, metabolic dysfunction, and risks associated with an elevated body mass index (BMI) have been observed. Herein, we aimed to assess the efficacy of vortioxetine in improving depressive symptoms among individuals with PCC, as modulated by inflammation, metabolic dysfunction, and BMI.
METHODS: In this post-hoc analysis, we present preliminary data obtained from an 8-week randomized, double-blind, placebo-controlled trial. Participants included adults aged 18 years and older residing in Canada who were experiencing symptoms of World Health Organization (WHO)-defined PCC. Recruitment began November 2021 and ended January 2023. Of the 200 participants enrolled, 147 were randomized (1:1) to receive vortioxetine (5-20 mg, n = 73) or placebo (n = 74) for daily treatment under double-blind conditions. The primary outcome measure was the change from baseline to endpoint in the 16-Item Quick Inventory of Depressive Symptomatology Self-Report Questionnaire (QIDS-SR-16).
RESULTS: Our findings revealed significant effects for time (χ2 = 9.601, p = 0.002), treatment (χ2 = 9.135, p = 0.003), and the treatment × time × CRP × TG-HDL × BMI interaction (χ2 = 26.092, p < 0.001) on PCC-related depressive symptoms in the adjusted model. Moreover, the between-group analysis showed a significant improvement with vortioxetine at endpoint as compared to placebo (mean difference = - 5.41, SEM = 1.335, p < 0.001).
CONCLUSION: Overall, vortioxetine significantly improved depressive symptoms among participants with PCC in the adjusted model. Notably, individuals with baseline markers of increased inflammation, metabolic disruption, and elevated BMI exhibited a more pronounced antidepressant effect at endpoint.
TRIAL REGISTRATION NUMBER: NCT05047952 (ClinicalTrials.gov).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Advances in therapy - (2024) vom: 23. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kwan, Angela T H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Body mass index (BMI) |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT05047952 Citation Status Publisher |
|---|
| doi: |
10.1007/s12325-024-02826-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370100662 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370100662 | ||
| 003 | DE-627 | ||
| 005 | 20240324235359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-024-02826-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370100662 | ||
| 035 | |a (NLM)38520501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kwan, Angela T H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition |b A Randomized Controlled Trial on Vortioxetine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05047952 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature. | ||
| 520 | |a INTRODUCTION: To date, there are no therapeutics that have gained regulatory approval by the United States Food and Drug Administration (FDA) for the treatment of post-COVID-19 condition (PCC), a debilitating condition characterized by cognitive impairment and mood symptoms. Additionally, persistent inflammation, metabolic dysfunction, and risks associated with an elevated body mass index (BMI) have been observed. Herein, we aimed to assess the efficacy of vortioxetine in improving depressive symptoms among individuals with PCC, as modulated by inflammation, metabolic dysfunction, and BMI | ||
| 520 | |a METHODS: In this post-hoc analysis, we present preliminary data obtained from an 8-week randomized, double-blind, placebo-controlled trial. Participants included adults aged 18 years and older residing in Canada who were experiencing symptoms of World Health Organization (WHO)-defined PCC. Recruitment began November 2021 and ended January 2023. Of the 200 participants enrolled, 147 were randomized (1:1) to receive vortioxetine (5-20 mg, n = 73) or placebo (n = 74) for daily treatment under double-blind conditions. The primary outcome measure was the change from baseline to endpoint in the 16-Item Quick Inventory of Depressive Symptomatology Self-Report Questionnaire (QIDS-SR-16) | ||
| 520 | |a RESULTS: Our findings revealed significant effects for time (χ2 = 9.601, p = 0.002), treatment (χ2 = 9.135, p = 0.003), and the treatment × time × CRP × TG-HDL × BMI interaction (χ2 = 26.092, p < 0.001) on PCC-related depressive symptoms in the adjusted model. Moreover, the between-group analysis showed a significant improvement with vortioxetine at endpoint as compared to placebo (mean difference = - 5.41, SEM = 1.335, p < 0.001) | ||
| 520 | |a CONCLUSION: Overall, vortioxetine significantly improved depressive symptoms among participants with PCC in the adjusted model. Notably, individuals with baseline markers of increased inflammation, metabolic disruption, and elevated BMI exhibited a more pronounced antidepressant effect at endpoint | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT05047952 (ClinicalTrials.gov) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Body mass index (BMI) | |
| 650 | 4 | |a Depressive symptoms | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Metabolic dysfunction | |
| 650 | 4 | |a Post-COVID-19 condition (PCC) | |
| 650 | 4 | |a Vortioxetine | |
| 700 | 1 | |a Guo, Ziji |e verfasserin |4 aut | |
| 700 | 1 | |a Ceban, Felicia |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Gia Han |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Teopiz, Kayla M |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Taeho Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Di Vincenzo, Joshua D |e verfasserin |4 aut | |
| 700 | 1 | |a Badulescu, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Meshkat, Shakila |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenblat, Joshua D |e verfasserin |4 aut | |
| 700 | 1 | |a d'Andrea, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Dev, Donovan A |e verfasserin |4 aut | |
| 700 | 1 | |a Phan, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniapillai, Mehala |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Roger S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g (2024) vom: 23. März |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02826-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 03 | ||